Patient Centered Research
Cardiome is an integrated, commercial, specialty pharmaceutical company dedicated to the development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems.
We have two marketed products approved in Europe and other territories BrinavessTM (vernakalant IV), for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults and Aggrastat® a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information visit ourInvestors section.
To develop and commercialize new therapies that will improve the quality of life and health of patients.